FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Teleflex Pacing Guidewire Cleared

FDA clears a Teleflex 510(k) for its Wattson Temporary Pacing Guidewire a bipolar temporary device designed specifically for use during transcatheter...

latest-news-card-1
Federal Register

ICH Guide on Good Clinical Practice

Federal Register notice: FDA makes available a draft guidance entitled E6(R3) Guideline for Good Clinical Practice.

latest-news-card-1
Federal Register

Braun EUA Revoked on Propofol-Lipuro

Federal Register notice: FDA revokes an emergency use authorization issued to B. Braun Melsungen AG for propofol-lipuro 1% injectable emulsion.

latest-news-card-1
Biologics

CBER Post-Covid Transition Information

CBER updates information for regulated entities on the return to normal operations with the end of the Covid-19 public health emergency.

latest-news-card-1
Biologics

Legend Bio sBLA to Expand Carvyktis Use

Legend Biotech files a supplemental BLA seeking to expand the label for Carvykti (ciltacabtagene autoleucel) to include the treatment of adult patient...

latest-news-card-1
Human Drugs

Eisai/Biogen Alzheimers Drug Effective: FDA

FDA medical reviewers ask members of the Peripheral and Central Nervous System Drugs Advisory Committee to confirm the benefits and risks of Eisai/Bio...

latest-news-card-1
Human Drugs

Bioresearch Monitoring Issues in Mazhar Trials

FDA warns Houston, TX-based physician Mobeen Mazhar about violations in conducting three clinical trials.

latest-news-card-1
Human Drugs

PMI Major Change in Drug Labeling: Attorneys

Five Hogan Lovells attorneys explain how an FDA proposal to require Patient Medication Information would represent a significant change in drug labeli...

latest-news-card-1
Human Drugs

FDA OKs Mercks Prevymis for Kidney Transplants

FDA approves Mercks Prevymis (letermovir) for prophylaxis of cytomegalovirus disease in adult kidney transplant recipients.

latest-news-card-1
Human Drugs

Adderall Shortage Process Muddy, Obscure: Wyden

Sen. Ron Wyden calls on FDA and the DEA to issue a joint statement on the current Adderall shortage and to answer questions about its work in addressi...